Epilepsy is a neurological disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness.&nbsp;
&nbsp;
Epilepsy signs and symptoms of seizures include temporary confusion, staring spell, uncontrollable jerking movements of the arms and legs, loss of consciousness or awareness, and psychic symptoms.&nbsp;
&nbsp;
Epilepsy Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Epilepsy in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Prevalent Population of Epilepsy</li>
<li>Total Diagnosed Prevalent Population of Epilepsy</li>
<li>Gender-specific Diagnosed Prevalent Population of Epilepsy</li>
<li>Diagnosed Prevalent Population of Epilepsy Based on Seizure types in Adults</li>
<li>Diagnosed Prevalent Population of Epilepsy Based on Seizure types in Children</li>
</ul>
&nbsp;
Epilepsy Epidemiology&nbsp;
<ul>
<li>The total prevalent population of Epilepsy in 7 MM was 7,190,297 in 2017.&nbsp;</li>
<li>The total prevalent population of Epilepsy in the United States was 3,579,732 in 2017.</li>
</ul>
&nbsp;
<a style="color: #0066cc;" href="https://www.delveinsight.com/report-store/epilepsy-market" target="_blank" rel="noopener noreferrer">Epilepsy Market</a>
The market size of Epilepsy in 7MM in 2017 was USD 1,847.46 Million.&nbsp;
&nbsp;
Epilepsy Market Drivers
<ul>
<li>Specialized multidisciplinary care</li>
<li>Constructive Efforts</li>
<li>Promising Emerging Therapies</li>
<li>Increase in R&amp;D</li>
<li>Government Initiatives and Funding</li>
</ul>
&nbsp;
Epilepsy Market Barriers
<ul>
<li>Generics in the Market</li>
<li>Low Compliance Rate</li>
<li>Heterogeneity Barrier</li>
<li>Differential Diagnosis</li>
<li>Therapeutic and Public Health Barriers</li>
<li>Challenges during Clinical Studies&nbsp;</li>
</ul>
&nbsp;
Epilepsy Emerging Drugs
The emerging&nbsp;drugs of the Epilepsy market are&nbsp;
<ul>
<li>Ganaxolone&nbsp;</li>
<li>AQST-203&nbsp;</li>
<li>Cannabidiol&nbsp;</li>
<li>Padsevonil&nbsp;</li>
<li>Soticlestat (TAK935/OV935)&nbsp;</li>
<li>Zygel (ZYN002)&nbsp;</li>
<li>ACT-709478/NBI-827104&nbsp;</li>
<li>Translarna (ataluren)&nbsp;</li>
<li>Vatiquinone (EPI-743)&nbsp;</li>
<li>JBPOS0101&nbsp;</li>
<li>Natalizumab&nbsp;</li>
<li>Staccato Alprazolam&nbsp;</li>
<li>ICV Delivery System of Valproic Acid (CT-010)&nbsp;</li>
<li>EPX-100 (Clemizole HCl)&nbsp;</li>
<li>JZP-385&nbsp;</li>
<li>XEN1101&nbsp;</li>
<li>PF-06372865/ CVL-865&nbsp;</li>
<li>STK-001&nbsp;</li>
</ul>
And many others.&nbsp;
&nbsp;
Epilepsy Key Players
The key players in the Epilepsy market are
<ul>
<li>Marinus Pharmaceuticals</li>
<li>Aquestive Therapeutics</li>
<li>Insys Therapeutics</li>
<li>UCB</li>
<li>Takeda</li>
<li>Ovid Therapeutics</li>
<li>Zynerba Pharma</li>
<li>Idorsia Pharmaceuticals</li>
<li>Neurocrine Biosciences</li>
<li>PTC Therapeutics</li>
<li>BioPharm Solutions</li>
<li>Biogen</li>
<li>Engage Therapeutics</li>
<li>Cerebral Therapeutics</li>
<li>Epygenix</li>
<li>Jazz Pharmaceuticals</li>
<li>Xenon Pharmaceuticals</li>
<li>Pfizer</li>
<li>Cerevel Therapeutics</li>
<li>Stoke Therapeutics</li>
</ul>
And many others.&nbsp;

Epilepsy Market

Epilepsy Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.